The management of autoimmune, inflammatory diseases has been revolutionised by biological therapies. A beneficial consequence of better disease control is that more patients are well enough to travel the world. There is now a class of traveller, the significantly immunosuppressed person with autoimmune disease, with specific risks and requirements. This review introduces the concept of the pre-travel risk assessment and discusses the major vaccine-preventable and non-vaccine-preventable travel-associated infections. The challenges and controversies around vaccination and immunosuppression are reviewed with advice for clinical practice. Please also advise patients travelling abroad to wear a seat belt and use condoms.
Victoria Allen, Nicky Longley